1Macrolide therapy thus seems to improve the outcome of severe ischaemic heart disease.
2Aim: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries.
3Main outcome: Blood pressure and prospectively assessed ischaemic heart disease.
4Methods: Antibody screening using protein arrays was performed in patients with angiographically-proven ischaemic heart disease.
5The purpose is to evaluate p38 inhibition as a potential therapy for ischaemic heart disease.
6Falling death rates from ischaemic heart disease are continuing to contribute to increasing life expectancy.
7Information about their lifestyle characteristics and first-degree family histories of ischaemic heart disease (i.e.
8Experimental data suggest that cell-based therapies may be useful for cardiac regeneration following ischaemic heart disease.
9Conclusions: Blood group A is related to the incidence of ischaemic heart disease in individual subjects.
10Main outcome measures: Subjects with ischaemic heart disease identified in 1991 by the Danish National Hospital Register.
11Cardiovascular diseases, principally ischaemic heart disease and stroke, are the leading causes of global mortality and morbidity.
12Conclusions: Concomitant amlodipine has no negative impact on clopidogrel-mediated platelet inhibition in patients with ischaemic heart disease.
13We studied 20 patients with ischaemic heart disease, who consistently developed complex ventricular arrhythmias during exercise testing.
14Results: Towns with a higher prevalence of blood group O had higher incidences of ischaemic heart disease.
15Prospective epidemiological studies have shown that elevated levels of fibrinogen are associated with thrombosis and ischaemic heart disease.
16In two minor controlled clinical trials, patients with ischaemic heart disease were randomised into antibiotic-treated and placebo groups.
Translations for ischaemic heart disease